Search Results
Your search for all items matches 24042 pages
Showing 51 - 100Expert Point of View: Fatima Cardoso, MD
The SOLAR-1 invited discussant, Fatima Cardoso, MD, Director of the Breast Unit at the Champalimaud Clinical Center in Lisbon and Chair of the ABC Global Alliance, commented: “The overall survival results, though numerically different by almost 8 months, unfortunately do not reach statistical...
Final Analysis of SOLAR-1: 8-Month Survival Benefit Misses Statistical Significance for Alpelisib
The statistically significant benefit of alpelisib in reducing disease progression, as reported at the European Society for Medical Oncology (ESMO) Congress 2 years ago, did not translate into a significant improvement in overall survival, although a numerical 8-month gain was observed in the final ...
AACR Announces Move to Virtual Meeting for 2021
The Annual Meeting of the American Association for Cancer Research (AACR) brings together key stakeholders in all areas of cancer research to make connections, build collaborations, and explore and expand the frontiers of integrative cancer science and medicine. After careful consideration of...
Growing Interest in Antiandrogens to Treat Male Breast Cancer
“There has been a lot of interest in the development of new antiandrogens” for clinical use in patients with breast cancer,” Anthony D. Elias, MD, reported in an update on male breast cancer at the 2020 Lynn Sage Breast Cancer Symposium, sponsored by the Robert H. Lurie Comprehensive Cancer Center...
Pembrolizumab in Adult and Pediatric Classical Hodgkin Lymphoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 14, 2020, the approval of pembrolizumab was...
Expert Point of View: David Cameron, MD
“This study highlights an interesting difference between breast cancers that are detected at the time a woman attends a scheduled appointment as part of a national screening program and those that are diagnosed in the interval between screenings,” commented European Breast Cancer Conference...
Mode of Detection of High-Risk Breast Cancer Linked to Prognosis
Breast cancers detected between mammographic screenings carry a worse prognosis than those detected at the time of screening, even when tumor biology is similar, according to research presented at the 12th European Breast Cancer Conference (EBCC 12), which was held virtually this year.1 The 8-year...
Expert Point of View: Keerthi Gogineni, MD, MSHP
Keerthi Gogineni, MD, MSHP, Assistant Professor of Hematology and a medical oncologist at Emory University School of Medicine, Atlanta, commented on the long-term follow-up of the MINDACT trial presented at the 12th European Breast Cancer Conference. She noted that, for patients with early-stage...
MINDACT at 8.7 Years: Primary Findings Confirmed
Long-term analysis of the phase III MINDACT trial, with a median follow-up of 8.7 years, confirmed that the 70-gene signature MammaPrint assay can identify which patients with breast cancer can safely forgo adjuvant chemotherapy, reported Emiel Rutgers, MD, PhD, FRCS, a surgical oncologist at the...
Hairy Cell Leukemia Foundation and Leukemia & Lymphoma Society Join Forces
The Hairy Cell Leukemia Foundation (HCLF) and The Leukemia & Lymphoma Society (LLS) recently announced they are teaming up to support a research grants program of up to $10 million over 5 years. Their goal is to build a more comprehensive understanding of hairy cell leukemia, develop better...
Expert Point of View: Emiliano Calvo, MD, and Udai Banerji, MD
Press briefing moderator and meeting Co-Chair, Emiliano Calvo, MD, Director of the START Madrid Group and Director of Clinical Research at the START Madrid-Centro Integral Oncologico Clara Campal Hospital, stated: “Using drugs that are already approved and in worldwide use, and to be able to...
Can Antihypertensives Improve Outcomes With Immunotherapy?
Angiotensin receptor blockers, commonly used to treat hypertension, may improve outcomes in patients treated with anti–PD-1/L1 agents, according to an observational study of almost 600 patients reported at the virtual 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.1 The...
Expert Point of View: Howard (Jack) West, MD, and William R. Sellers, MD
Howard (Jack) West, MD, Associate Clinical Professor in Medical Oncology at City of Hope Comprehensive Cancer Center, Duarte, California, was impressed with the data from the KRYSTAL-1 trial. “It’s great to see new data on another entrant into the space for patients with KRAS G12C...
KRAS Inhibitor Adagrasib Shows Activity in Non–Small Cell Lung Cancer
Another novel oral KRAS inhibitor—adagrasib (MRTX849)—has shown promise in early clinical trials, according to investigators of the KRYSTAL-1 study who reported findings at the virtual 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.1,2 The conference is jointly provided...
Daniel Sullivan, MD, Honored for Leadership in Quantitative Imaging Biomarkers
The Prevent Cancer Foundation recently honored Daniel C. Sullivan, MD, with the James L. Mulshine, MD Leadership Award for his work in founding and chairing the Quantitative Imaging Biomarkers Alliance (QIBA). The Quantitative Imaging Biomarkers Alliance is committed to attempting to transform...
Expert Point of View: Melina E. Marmarelis, MD, MSCE
Invited study discussant, Melina E. Marmarelis, MD, MSCE, of Abramson Cancer Center at the University of Pennsylvania, Philadelphia, noted that pembrolizumab has been evaluated in advanced mesothelioma in several clinical trials, with varying results. According to Dr. Marmarelis, this high...
Use of Pembrolizumab in Advanced Pleural Mesothelioma: Results From KEYNOTE-158
The largest single-arm trial evaluating pembrolizumab in relapsed malignant pleural mesothelioma has demonstrated an “impressive” duration of response, according to a presentation during the virtual edition of the International Association for the Study of Lung Cancer (IASLC) 2020 North America...
Nagi S. El Saghir, MD, FACP, FASCO, Receives Lebanon’s National Cedar Medal Award
One of Lebanon’s highest national awards, the National Cedar Medal (Commander Rank), was recently bestowed upon Nagi S. El Saghir, MD, FACP, FASCO, in recognition of his extensive contributions to the fields of medicine, education, and science—and most particularly, for his efforts in the fight...
Stereotactic Radiosurgery May Delay Cognitive Deterioration vs Whole-Brain Radiotherapy for Multiple Brain Metastases
Stereotactic radiosurgery appears to be a new standard of care for patients with four or more nonmelanoma brain metastases, perhaps replacing whole-brain radiotherapy in this setting, according to a potentially practice-changing phase III study presented at the 2020 American Society for Radiation...
Expert Point of View: Kristin J. Redmond, MD, MPH
Formal discussant of the CCTG SC.24/TROG 17.06 trial, Kristin J. Redmond, MD, MPH, of The Johns Hopkins University School of Medicine, Baltimore, expressed confidence in the findings of Dr. Sahgal’s study. “We now have level 1 data to support a stereotactic body radiation therapy (SBRT) dose of 24 ...
Management of Painful Spinal Metastases: SBRT vs Conventional Radiotherapy
Stereotactic body radiation therapy (SBRT) was superior to conventional radiation therapy in reducing pain from spinal metastases in a phase II/III study reported at the virtual edition of the 2020 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 More than twice as many patients...
Analysis Seeks to Identify Characteristics of 'Exceptional Responders' to Cancer Therapy
In a comprehensive analysis of patients with cancer who had exceptional responses to therapy, researchers identified molecular changes in the patients’ tumors that may explain some of these outcomes. The results, published by Wheeler et al in Cancer Cell, demonstrated that genomic characterizations ...
ESMO Asia 2020: Phase III GEMSTONE-302 Trial Finds CS1001 Plus Platinum Chemotherapy Prolongs Progression-Free Survival in NSCLC
The addition of CS1001, an anti–PD-L1 monoclonal antibody, to platinum-based chemotherapy significantly prolonged progression-free survival vs chemotherapy in treatment-naive patients with advanced non–small cell lung cancer (NSCLC), according to phase III findings presented by Zhou et al at the...
Image-Guided IMRT Reduces GI Toxicity Without Compromising Pelvic Recurrence in Intermediate- to High-Risk Cervical Cancer
Post-hysterectomy image-guided intensity-modulated radiation therapy (IMRT) was superior to three-dimensional conformal radiation therapy (3D-CRT) in reducing the side effects of pelvic radiation while achieving similar tumor control in women with high-risk cervical cancer, according to the final...
Impact of COVID-19 on Cancer Care in India
With the announcement of a complete nationwide lockdown on March 25, 2020, to prevent the spread of COVID-19, a lot of unprecedented events came into being in India. The National Health Mission reported a 69% reduction in measles, mumps, and rubella vaccination in children; a 21% reduction in...
ESMO Asia 2020: Phase II Study Investigates Efficacy of Anlotinib in Radioiodine-Refractory Differentiated Thyroid Cancer
Patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma demonstrated a statistically significant progression-free survival benefit when treated with anlotinib, a novel tyrosine kinase inhibitor, vs placebo, as well as higher response rates, according to...
Expert Point of View: Deborah B. Doroshow, MD, PhD
Invited study discussant, Deborah B. Doroshow, MD, PhD, Assistant Professor of Medicine at the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, in New York, noted that the current first-line treatment paradigm for patients with advanced NSCLC and no driver mutation is based on...
ESMO Asia 2020: First-Line Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma
Sintilimab, an anti–PD-1 antibody, in combination with a bevacizumab biosimilar as first-line therapy significantly improved survival compared to sorafenib in patients with advanced hepatocellular carcinoma, according to findings presented by Ren et al at the ESMO Asia Virtual Congress 2020...
Nivolumab Plus Ipilimumab in First-Line NSCLC: Two New Indications, Many More Questions
In May 2020, the combination of nivolumab and ipilimumab was approved by the U.S. Food and Drug Administration (FDA) for two separate indications in the first-line setting of advanced non–small cell lung cancer (NSCLC). One was in metastatic NSCLC with tumors that have PD-L1 expression ≥ 1% with...
Fluciclovine PET Imaging Benefits Radiotherapy Treatment Planning Compared With Conventional Imaging in Prostate Cancer
The addition of the radiotracer fluciclovine to positron-emission tomography (PET) imaging for radiotherapy treatment planning led to superior failure-free survival compared with conventional imaging in men with prostate cancer who had undergone radical prostatectomy and were experiencing biologic ...
Reconstruction Implant Surface Texture and Risk of Breast Cancer Recurrence
In a Korean single-institution cohort study reported in JAMA Surgery, Lee et al found that the use of textured surface implants in breast reconstruction following mastectomy for breast cancer was associated with poorer disease-free survival. Study Details The study involved data from 650 women...
Adoption of Hypofractionated Radiation Therapy After Change in Prostate Cancer Clinical Pathway
In a study reported in JCO Oncology Practice, Schad et al found that modifying the prostate cancer clinical pathway in an integrated oncology network to designate moderately hypofractionated external-beam radiotherapy (mHF-EBRT) as the recommended curative EBRT monotherapy in low- and...
Once-Weekly Selinexor Plus Bortezomib/Dexamethasone vs Twice-Weekly Bortezomib/Dexamethasone in Previously Treated Patients With Multiple Myeloma
As reported in The Lancet by Grosicki et al, the phase III BOSTON trial has shown significantly prolonged progression-free survival with once-weekly selinexor plus bortezomib/dexamethasone vs twice-weekly bortezomib/dexamethasone in previously treated patients with multiple myeloma. Study Details...
Expert Point of View: Alejandro Berlin, MD, MSc
Discussant of the abstract, Alejandro Berlin, MD, MSc, Assistant Professor at the Princess Margaret Cancer Centre, Toronto, called the study “thought-provoking” and applauded the data-sharing approach to answer a clinically relevant question. According to Dr. Berlin, this work resurfaces the...
Adjuvant vs Neoadjuvant Androgen-Deprivation Therapy With Radiotherapy for Prostate Cancer
Sequencing of androgen-deprivation therapy with radiotherapy has a significant impact on long-term outcomes in localized prostate cancer, according to data presented during the virtual edition of the 2020 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 Pooled individual patient...
ESMO Asia 2020: Futibatinib for Patients With Refractory Intrahepatic Cholangiocarcinoma and FGFR2 Fusions/Rearrangements
Clinical benefit was provided by the FGFR1–4 inhibitor futibatinib in patients with refractory intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements, including those enrolled in Asian countries. These findings were presented by Furuse et al at the ESMO Asia Virtual...
ESMO Asia 2020: Novel PD-L1 Antibody Shows Activity in Advanced MSI-H/dMMR Tumors
Envafolimab (also known as KN035), a novel PD-L1 antibody, demonstrated antitumor activity and was safe in patients with diverse, advanced microsatellite instability–high/mismatch repair–deficient (MSI-H/dMMR) tumors, according to findings presented by Shen et al at the ESMO Asia Virtual Congress...
ESMO Asia 2020: Early Detection and Localization of Cancer Using a Blood-Based Assay
The ELSA-seq assay was able to detect diverse cancer types at early stages with high specificity and was able to provide information regarding the tissue of origin, according to findings presented by Gao et al at the ESMO Asia Virtual Congress 2020 (Abstract LBA3). Qiang Gao, MD, PhD, of the Liver...
ESMO Asia 2020: Baseline Characteristics of Asian Patients Enrolled in the monarchE Trial
A comparison of baseline characteristics in patients with hormone receptor (HR)-positive, HER2-negative early breast cancer revealed that a higher proportion of patients enrolled from Asia had risk factors for disease recurrence than those enrolled from non-Asian countries, reported Jiang et al at...
First-Line Lorlatinib vs Crizotinib in Advanced ALK-Positive NSCLC
As reported in The New England Journal of Medicine by Alice T. Shaw, MD, PhD, and colleagues, an interim analysis of the phase III CROWN trial has shown that first-line lorlatinib significantly improved progression-free survival and intracranial response rate vs crizotinib in patients with advanced ...
ASCO Announces Julie R. Gralow, MD, FACP, FASCO, as New Chief Medical Officer
Julie R. Gralow, MD, FACP, FASCO, Professor of Medical Oncology and Director of Breast Medical Oncology at the University of Washington, Fred Hutchinson Cancer Research Center, and the Seattle Cancer Care Alliance, has been named the next Chief Medical Officer of ASCO. Dr. Gralow will succeed...
Effect of Anterior Approach vs Conventional Hepatectomy in Resection of Colorectal Liver Metastases on Intraoperative Tumor Cell Dissemination
In a German single-institution study reported in JAMA Surgery, Rahbari et al found that the anterior approach to the resection of colorectal liver metastases was not associated with a reduction in the detection of intraoperative circulating tumor cells vs conventional hepatectomy. As stated by the...
Pembrolizumab Plus Bevacizumab and Oral Metronomic Cyclophosphamide for Recurrent Ovarian Cancer
In a single-institution phase II trial reported in JAMA Oncology, Zsiros et al found that the combination of pembrolizumab with bevacizumab and oral metronomic cyclophosphamide produced objective response in approximately half of women with recurrent ovarian cancer taking part in the study....
FDA Announces Advisory Committee Meeting to Discuss COVID-19 Vaccine Candidate
The U.S. Food and Drug Administration (FDA) has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) for December 10, 2020, to discuss the request for emergency use authorization (EUA) of a COVID-19 vaccine from Pfizer, in partnership with BioNTech. “The...
Emergency Use Authorization Request to Be Submitted to FDA Today for COVID-19 Vaccine
Pfizer Inc and BioNTech SE announced they will submit a request today to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization of their mRNA vaccine candidate, BNT162b2 against SARS-CoV-2, which will potentially enable use of the vaccine in high-risk populations in the United...
COVID-19: Infection Rate Among Patients Undergoing Anticancer Therapy and Its Effect on Cancer Clinical Trials
As COVID-19 infection rates again spike around the nation, this week, we’re looking at two recent studies focused on COVID-19 and cancer. The first describes the rate of infection with the virus among asymptomatic patients with cancer undergoing active treatment for their solid tumors. The second...
4-Year Findings From MURANO Trial: Venetoclax Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia
As reported in the Journal of Clinical Oncology by Arnon P. Kater, MD, PhD, of Amsterdam University Medical Centers, and colleagues,1 the 4-year progression-free and overall survival rates were significantly higher with venetoclax plus rituximab vs bendamustine plus rituximab in the phase III...
Final ASCEND Results Confirm Acalabrutinib as a Standard for Relapsed CLL
The Bruton’s tyrosine kinase (BTK) inhibitors have been one of the most exciting advances in the treatment of patients with chronic lymphocytic leukemia (CLL) and have led to the development of chemotherapy-free treatments for both treatment-naive as well as relapsed or refractory CLL based on...
Acalabrutinib Improves Progression-Free Survival vs Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory CLL
As reported in the Journal of Clinical Oncology by Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele, Milan, Italy, and colleagues, the phase III ASCEND trial showed significantly prolonged progression-free survival with acalabrutinib monotherapy vs investigator’s choice of either...
Carfilzomib vs Bortezomib, Each Combined With Lenalidomide/Dexamethasone, in Newly Diagnosed Patients With Multiple Myeloma
As reported in The Lancet Oncology by Shaji K. Kumar, MD, of the Division of Hematology, Mayo Clinic, Rochester, and colleagues,1 the phase III ENDURANCE trial has shown no improvement in progression-free survival with carfilzomib plus lenalidomide/dexamethasone (KRd) vs bortezomib plus...
